This inventor holds 4 USPTO granted patents and 3 published patent applications. Top assignees: Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu University of Technology. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 2 
2 out of 26 
1 out of 81 Years Active: 2024-2026
Title: Cheng Wang: Innovator in Therapeutic Antibodies
Introduction
Cheng Wang is a prominent inventor based in Chengdu, China, known for his significant contributions to the field of therapeutic monoclonal antibodies. With a total of 4 patents, his work focuses on innovative solutions for medical treatments, particularly in oncology and coagulation disorders.
Latest Patents
Cheng Wang's latest patents include groundbreaking inventions such as the anti-CLDN18.2 antibody. This invention provides an anti-CLDN18.2 antibody or an antigen-binding fragment, along with nucleic acid molecules for encoding the antibody and methods for its preparation. The antibody exhibits high specificity and affinity to CLDN18.2, effectively binding to and mediating the killing of CLDN18.2 expressing cells. Additionally, it includes a pharmaceutical composition for the prevention and treatment of tumors. Another notable patent is the anti-FXI/FXIa antibody, which relates to therapeutic monoclonal antibodies. This invention offers an anti-FXI/FXIa antibody or an antigen-binding fragment, along with nucleic acid molecules encoding the antibody. It effectively inhibits the activity of FXI/FXIa and provides a pharmaceutical composition for the prevention and treatment of coagulation-related diseases.
Career Highlights
Cheng Wang has worked with notable companies in the biopharmaceutical sector, including Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Klus Pharma Inc. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.
Collaborations
Cheng has collaborated with esteemed colleagues such as Haijun Tian and Dengnian Liu, further enhancing his research and development efforts in the field of biopharmaceuticals.
Conclusion
Cheng Wang's innovative work in therapeutic antibodies showcases his commitment to advancing medical science. His patents reflect a dedication to improving treatment options for patients, particularly in oncology and coagulation disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile